ArticleCancer journal (Sudbury, Mass.)

Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.

Gege Gui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.